{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029326","form_type":"8-K","ticker":"NRXS","cik":"0001933567","company_name":"Neuraxis, INC","filed_at":"2023-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.087214+00:00","generated_at":"2026-06-11T08:03:48.140069+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeurAxis reports over $8M in cumulative IB-Stim revenue through March 31, 2023","bullets":["Over $8M in revenue from IB-Stim since commercial launch after FDA clearance for pediatric functional abdominal pain and IBS.","Approximately $2M of total revenue was generated in 2019 and 2020.","Company is conducting clinical trials for four additional pediatric indications: chronic nausea, post-concussion syndrome, chemo-induced nausea, and cyclic vomiting.","CEO Brian Carrico cites growing adoption, non-drug therapy trend, and recently completed IPO funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029326","json":"https://secwatch.observer/filing/0001493152-23-029326.json","markdown":"https://secwatch.observer/filing/0001493152-23-029326.md","text":"https://secwatch.observer/filing/0001493152-23-029326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933567/000149315223029326/0001493152-23-029326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933567/000149315223029326/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:03:48.140069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}